Coherus Biosciences (CHRS) Releases Earnings Results, Misses Estimates By $0.08 EPS

Coherus Biosciences (NASDAQ:CHRS) issued its quarterly earnings results on Thursday. The biotechnology company reported ($0.87) EPS for the quarter, missing analysts’ consensus estimates of ($0.79) by ($0.08), Morningstar.com reports.

CHRS stock traded down $1.88 during trading hours on Friday, hitting $10.06. 2,369,603 shares of the stock traded hands, compared to its average volume of 892,346. Coherus Biosciences has a one year low of $8.05 and a one year high of $20.66. The stock has a market capitalization of $846.40 million, a P/E ratio of -2.24 and a beta of 3.72. The company has a quick ratio of 7.79, a current ratio of 7.79 and a debt-to-equity ratio of 1.66.

In related news, insider Barbara K. Finck sold 1,760 shares of the firm’s stock in a transaction dated Monday, September 10th. The stock was sold at an average price of $18.58, for a total transaction of $32,700.80. Following the completion of the transaction, the insider now owns 38,803 shares of the company’s stock, valued at $720,959.74. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director James Healy sold 25,000 shares of the firm’s stock in a transaction dated Wednesday, August 29th. The shares were sold at an average price of $20.50, for a total value of $512,500.00. The disclosure for this sale can be found here. Insiders have sold 28,520 shares of company stock valued at $578,676 in the last ninety days. Company insiders own 26.28% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the stock. BlueMountain Capital Management LLC acquired a new position in shares of Coherus Biosciences in the 2nd quarter valued at $214,000. Royal Bank of Canada boosted its position in shares of Coherus Biosciences by 26.2% in the 1st quarter. Royal Bank of Canada now owns 32,526 shares of the biotechnology company’s stock valued at $360,000 after purchasing an additional 6,754 shares during the period. Fox Run Management L.L.C. acquired a new position in shares of Coherus Biosciences in the 2nd quarter valued at $266,000. Tower Research Capital LLC TRC acquired a new position in shares of Coherus Biosciences in the 2nd quarter valued at $118,000. Finally, Swiss National Bank boosted its position in shares of Coherus Biosciences by 7.6% in the 2nd quarter. Swiss National Bank now owns 70,500 shares of the biotechnology company’s stock valued at $987,000 after purchasing an additional 5,000 shares during the period. 91.25% of the stock is owned by institutional investors and hedge funds.

CHRS has been the subject of several research reports. ValuEngine raised Coherus Biosciences from a “hold” rating to a “buy” rating in a research note on Thursday, July 19th. Zacks Investment Research cut Coherus Biosciences from a “hold” rating to a “sell” rating in a research note on Monday, August 13th. BidaskClub raised Coherus Biosciences from a “hold” rating to a “buy” rating in a research note on Friday, August 24th. HC Wainwright initiated coverage on Coherus Biosciences in a research note on Tuesday, August 28th. They set a “buy” rating and a $28.00 target price for the company. Finally, Maxim Group reaffirmed a “buy” rating and set a $25.00 target price on shares of Coherus Biosciences in a research note on Tuesday, September 25th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the stock. Coherus Biosciences has an average rating of “Buy” and a consensus price target of $27.20.

COPYRIGHT VIOLATION NOTICE: This piece was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be read at https://www.americanbankingnews.com/2018/11/10/coherus-biosciences-chrs-releases-earnings-results-misses-estimates-by-0-08-eps.html.

Coherus Biosciences Company Profile

Coherus BioSciences, Inc, a biosimilar company, develops and commercializes various therapeutic products worldwide. The company engages in the development of late-stage clinical products, including CHS-1701 pegfilgrastim biosimilar, a granulocyte colony-stimulating factor product candidate; CHS-1420 adalimumab biosimilar, an anti-tumor necrosis factor product candidate; and CHS-0214, an etanercept biosimilar for rheumatoid arthritis and psoriasis.

Featured Story: Balanced Fund

Earnings History for Coherus Biosciences (NASDAQ:CHRS)

Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply